References
- Schultze JL, Rosenstiel P, The SYSCID consortium. Systems medicine in chronic inflammatory diseases. Immunity 2018;48:608–13.
- Mazarakis N, Snibsond K, Licciardi PV, Karagiannis TC. The potential use of l-sulforaphane for the treatment of chronic inflammatory diseases: a review of the clinical evidence. Clin. Nutr 2019;38:pii: S0261-5614(19)30136-0.
- Wu Y, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett 2014;345:164–73.
- Hanke T, Merk D, Steinhilber D, et al. Small molecules with anti-inflammatory properties in clinical development. Pharmacol. Ther 2016;157:163–87.
- PatronoRocca CB. Nonsteroidal antiinflammatory drugs: past, present and future. Pharm Res 2009;59:285–9.
- Pratsinis YH, Papadopoulou YA, Neidlinger Wilke C, et al. Cyclic tensile stress of human annulus fibrosus cells induces MAPK activation: involvement in proinflammatory gene expression. Osteoarthritis Cartilage 2016;24:679–87.
- Navarrete CM, Pérez M, de Vinuesa AG, et al. Endogenous N-acyl-dopamines induce COX-2 expression in brain endothelial cells by stabilizing mRNA through a p38 dependent pathway. Biochem Pharmacol 2010;79:1805–14.
- Lötsch J, Geisslinger G. Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. Drug Discov Today 2011;16:1001–6.
- Ma X, Lv X, Zhang J. Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): an update of recent medicinal chemistry efforts. Eur J Med Chem 2018;143:449–63.
- Schierle S, Flauaus C, Heitel P, et al. Boosting anti-inflammatory potency of zafirlukast by designed polypharmacology. J Med Chem 2018;61:5758–64.
- Proschak E, Stark H, Merk D. Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds. J. Med. Chem 2019;62:420–44.
- Bolognesi ML. Harnessing polypharmacology with medicinal chemistry. ACS Med Chem Lett 2019;10:273–5.
- Gilberg E, Bajorath J. Recent progress in structure-based evaluation of compound promiscuity. ACS Omega 2019;4:2758–65.
- Murali Dhar TG, Wrobleski ST, Lin S, et al. Synthesis and SAR of p38a MAP kinase inhibitors based on heterobicyclic scaffolds. Bioorg Med Chem Lett 2007;17:5019–24.
- Laufer S, Lehmann F. Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase. Bioorg Med Chem Lett 2009;19:1461–4.
- (a) Sloan KB, Koch SAM. Effect of nucleophilicity and leaving group ability on the sn2 reactions of amines with (acyloxy)alkyl α-halides: a product distribution study. J Org Chem 1983;48:635–40.; (b) Reich SH, Melnick M, Pino MJ, et al. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series. J Med Chem 1996;39:2781–94.
- Xu X, Xiao W, Zhang Z, et al. Anti-pruritic and anti-inflammatory effects of oxymatrine in a mouse model of allergic contact dermatitis. J Dermatol Sci 2018;91:134–41.
- Beck PL, Li Yan, Wong J, et al. Inducible nitric oxide synthase from bone marrow-derived cells plays a critical role in regulating colonic inflammation. Gastroenterology 2007;132:1778–90.
- Lind M, Hayes A, Caprnda M, et al. Inducible nitric oxide synthase: good or bad? Biomed Pharmacothe 2017;93:370–5.
- Capece D, Verzella D, Tessitore A, et al. Cancer secretome and inflammation: the bright and the dark sides of NF-κB. Semin Cell Dev Biol 2018;78:51–61.
- Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717–26.
- Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. Semin Immunol 2014;26:237–45.
- Kulmacz RJ, Lands WEM. Requirements for hydroperoxide by the cyclooxygenase and peroxidase activities of prostaglandin H synthase. Prostaglandins 1983;25:531–40.
- Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644–8.
- Rowlinson SW, Kiefer JR, Prusakiewicz JJ, et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 2003;278:45763–9.
- Mavunkel BJ, Perumattam JJ, Tan X, et al. Piperidine-based heterocyclic oxalyl amides as potent p38α MAP kinase inhibitors. Bioorg Med Chem Lett 2010;20:1059–62.
- Morris GM, Huey R, Olson AJ. Using AutoDock for ligand-receptor docking. Curr Protoc Bioinformatics 2008;8:8–14.
- Lill MA, Danielson ML. Computer-aided drug design platform using PyMOL. J Comput Aid Mol Des 2011;25:13–9.